Stage Set For India To Frame Compulsory Licensing Provisions As Contrasting Groups Make Their Case
This article was originally published in The Pink Sheet Daily
Executive Summary
The Department of Industrial Policy and Promotion is analyzing and interpreting comments on a contentious subject that has kept Indian and multinational drug firms bitterly divided for more than five years, while forcing the government into a dilemma over an acceptable policy.
You may also be interested in...
PhRMA Meets With Indian Officials To Discuss Compulsory Licensing
Executives of the Pharmaceutical Research and Manufacturers of America were in India the last two weeks of October for meetings with member companies. One issue had grabbed their attention: India’s move toward compulsory licensing.
PhRMA Meets With Indian Officials To Discuss Compulsory Licensing
Executives of the Pharmaceutical Research and Manufacturers of America were in India the last two weeks of October for meetings with member companies. One issue had grabbed their attention: India’s move toward compulsory licensing.
Indian Firms Must Be In Indian Hands, Says Government Paper; Highlights Threats to Compulsory Licensing And Drug Pricing
MUMBAI - Ambitions of leading multinational companies for a long-term positioning in India through acquisition of generic companies may face rigid policy restrictions from a government concerned about monopoly-dictated pricing for needed drugs